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Therapy for Tuberculous Meningitis
To the Editor: Heemskerk et al. (Jan. 14 issue)1
report no survival benefit for intensified antituberculosis treatment for patients with tuberculous meningitis in Vietnam, a finding that was
contrary to the results of our study in Indonesia.2
Our unblinded study was smaller and had a higher proportion of patients with advanced tuberculous meningitis. However, we think that the
contrasting results are explained by the dose of
rifampin that was administered. The Vietnam
study compared 10 mg of rifampin per kilogram
of body weight per day with an increased dose of
15 mg of rifampin per kilogram, whereas we
evaluated 13 mg of rifampin per kilogram administered intravenously. The high dose used in
our study resulted in an increase in rifampin exposure in blood and cerebrospinal fluid by a factor of 3, with a relationship between the drug
level and the therapeutic response.3 In our study,
38% of patients who were receiving 13 mg of rif
ampin per kilogram had drug exposure that was
lower than the target exposure, which suggests
that the dose was not high enough.
Recent trial data for pulmonary tuberculosis
also support higher doses of rifampin than that
used in the Vietnam study. Regimens consisting
of doses of less than 35 mg of rifampin per kilogram did not reduce the time to culture conversion.4 We are currently evaluating similarly increased rifampin doses for the treatment of
tuberculous meningitis to prepare for a phase 3
trial. Pharmacokinetic and pharmacodynamic
analyses may show how many patients in the
Vietnam trial with its modest dose increase
reached target exposures of rifampin.3
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To the Editor: Heemskerk et al. investigated
an “intensified” treatment for tuberculous meningitis and did not find a higher survival rate
than that with standard treatment. We think
that the dose of rifampin was too low. We have
shown that doses up to 35 mg per kilogram are
tolerated.1,2 The authors suggest that the benefits of rifampin may be modest. Our data show
that higher doses of rifampin were associated
with a faster decline in the bacterial load, which
suggests that enhanced efficacy can occur with
higher doses. Thus, it is difficult to draw conclusions about the failure of the experimental
regimen when the trial regimen was possibly suboptimal.
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To the Editor: The study by Heemskerk et al.
raises important questions about the approach to
the treatment of tuberculous meningitis. The
Kaplan–Meier curve for mortality in the subgroup with grade 3 disease according to British
Medical Research Council criteria appeared to
favor the intensified-treatment regimen until it
began to converge with that of the standardtreatment regimen around day 150. A brief, but
less substantial, divergence of the curves was
seen early on in other subgroups as well. This
raises the question as to whether a more prolonged intensive-treatment strategy might be
beneficial. This approach is not without precedent, as described by Donald et al. in the editorial accompanying the article1 and in a study of
intensive therapy.2 Although most new regimens
that are evaluated have focused on reducing the
duration of treatment or modifying the intensive
phase in patients with pulmonary tuberculosis,3
perhaps the use of multiple drugs for longer periods may have an effect on mortality in patients
with tuberculous meningitis.
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The authors reply: We agree with all three
groups of correspondents that higher doses of
rifampin, perhaps given throughout treatment
after initial intravenous administration, may yet
improve outcomes for patients with tuberculous
meningitis. This effect, however, is predicated on
the hypothesis that enhanced intracerebral killing of Mycobacterium tuberculosis by “intensified”
antituberculosis treatment will increase survival
from tuberculous meningitis.
There are good reasons to question this hypothesis. First, our trial tested the addition of
higher-dose rifampin and levofloxacin to standard
four-drug treatment for the first 2 months of
therapy. Leaving aside the chosen rifampin dose,
levofloxacin is highly active against M. tuberculosis, and oral administration of the dose used in
the trial achieves high concentrations in the cerebrospinal fluid.1 Yet the addition of levofloxacin
to treatment had no discernible effect on survival from tuberculous meningitis.
Unlike pulmonary tuberculosis, tuberculous
meningitis is caused by a small number of bacteria. This fact hampers both the microbiologic
diagnosis and investigations linking drug exposures with destruction of bacteria and clinical
outcomes, but neither the bacterial load in cerebrospinal fluid nor the time to its sterility has
ever been clearly linked with survival among
patients with tuberculous meningitis.2 Instead,
the clinical outcome has been much more closely associated with the intracerebral inflammatory response, which may explain why the use of
adjunctive glucocorticoids improves survival3 and
why intensifying antituberculosis treatment has
so far met with limited success.
In addition, increased doses of antituberculosis drugs increase the risk of drug-induced hepatic
toxicity. In patients with pulmonary tuberculosis,
this complication can usually be managed safely
by stopping the drugs and reintroducing them
slowly. But in patients with tuberculous meningitis, any interruption in treatment with antituberculosis drugs is an independent risk factor
for death.3 This suggests that any potential survival benefit of intensified regimens may be offset
by even moderately increased toxicity and consequent reductions in dose or withdrawal of drugs.
In patients with tuberculous meningitis, survival depends on controlling inflammation and
killing bacteria before the development of complications of advanced disease: hydrocephalus,
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Planned Out-of-Hospital Birth and Birth Outcomes
To the Editor: Snowden et al. (Dec. 31 issue)1
report increased mortality among neonates in
Oregon whose mothers had planned out-of-hospital births and therefore corroborate our previous findings of significantly increased risks of
perinatal deaths and neonatal seizures among
neonates whose mothers had out-of-hospital
births in the United States.2-4 Snowden et al. undeniably underestimate the absolute and relative
neonatal risks associated with out-of-hospital
births, specifically with home births. First, they
lump together the outcomes for infants born in
birthing centers (which are associated with better
outcomes and have a better selection of patients)
with the outcomes for those whose mothers had
planned home births.2 Second, they excluded deliveries associated with higher risk (twins, breech
births, and anomalous births).1 Both the absolute
risk and the relative risk of death for infants
whose mothers have home births are therefore
likely to be even greater than the authors report.
Reducing the risks of childbirth is an ethical imperative for professionals in perinatal care who
are committed to increasing the safety and improving the quality of childbirth.5 Women planning an out-of-hospital birth should be informed
of the modern perinatal interventions available
in the hospital that are often lifesaving and can
prevent the increased neonatal risks associated
with planned out-of-hospital births.
n engl j med 374;22
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To the Editor: Snowden et al. report higher
rates of perinatal death, depressed 5-minute
Apgar scores, neonatal seizures, and maternal
blood transfusions among births that occur out
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